

Apollo Hospitals signs agreement with Accuray Inc.

29 March 2018 | News

New Systems Will Improve the Treatment Process Workflow, Enabling Clinicians to Treat More Patients Every Day.



Personalized, precise, radiation treatments will soon be available to more cancer patients in India. Accuray Incorporated has announced that the company has signed an agreement with the Apollo Hospitals Group in Chennai and New Delhi, India, for the acquisition of two Radixact Systems, radiation therapy devices that have been proven to deliver highly accurate treatments for a broad range of tumors anywhere in the body. The installation of these systems, one replacing a conventional linear accelerator and the other in a new vault, will expand access to state-of-the-art cancer treatment technology for the people of India. The orders were entered into backlog during Accuray Incorporated's Q3 fiscal quarter, which ends March 31, 2018.

Apollo Hospitals was established in 1983 and has since emerged as Asia's foremost integrated healthcare services provider. This patient-centric organization's mission is to bring the highest standards of healthcare to every patient.

Dr. Prathap C. Reddy, Chairman, Apollo Hospitals Group said, "Cancer care requires passionate commitment, cutting edge expertise along with unswerving dedication to keep raising the bar and at Apollo we have embraced this ethos, as our singular goal is to make cancer conquerable!"

Dr. Reddy added, "For over twenty-five years, Apollo Cancer Centres have been serving patients from over 140 countries. Our fine teams of Oncologists persevere relentlessly to offer patients the global best in cancer care and a contemporary product such as the Radixact System will help our patients by minimizing the impact on their quality of life."

"We are honored to be partnering with Apollo Hospitals to improve the lives of people with cancer. Our employees are focused on a common goal – to put patients first by providing them with the best possible care," said Lionel Hadjadjeba, M.D., Senior Vice President, and Chief Commercial Officer at Accuray. "The Radixact System can be used to treat virtually any tumor type including breast, head and neck, lung and prostate cancers, during every stage of the treatment journey, from primary cases, to recurrent and metastatic diseases. This gives the Apollo Hospitals clinical team tremendous flexibility and enables them to tailor treatments to the specific needs of each patient."